Member Info for EmeraldCarrots

Sales team have done assuming the half year report is published in an RNS tomorrow before the bell. My gut feeling is I won't be able to as, frankly to date they are not going to win any sales awards anytime soon. If they have not performed yet again I pray something is done about it. I am a share holder.

All IMHO.

Report, tomorrow should be interesting.

Up at least to evaluate the two machines. Especially the MT-RNR1 which tests to see if a baby can be given aminoglycoside antibiotics without being possibly rendered deaf by a bad reaction to the drugs. This point to me is a sales persons dream come true, but frankly the sales team at GDR IMHO have not to date capitalised on this, which I find totally astoninshing. Totally.

I think 60 to 80 MT-RNR1 machines are now in use 7 days a week. The number of CYP2C19 machines in use is more difficult as there are less RNS's to judge. My guess would be 25 to 35. However IMHO take up of the CYP2C19, which checks to make sure the patient will respond to Clopidogrel after a stroke, is likely to accelerating fast. I think sales will outstrip the MT-RNR1 in the next 6 months.

All IMHO.

I should think that would be a minimum good idea!

Countries, along with the USA will have to get together and open it up, whether they want to or not. Once it is secured I suspect Iran will find it wont be able to close it again, ever. The rest of the World will keep control going forward (from say 4 weeks time).

All IMHO.

So IMHO they must be happening, whatever some in Iran say.

Hmm.

The two machines by now in a similar way to the Saudis. I think 60 to 80 MT-RNR1 machines are now in use 7 days a week. The number of CYP2C19 machines in use is more difficult as there are less RNS's to judge. My guess would be 25 to 35. However IMHO take up of the CYP2C19, which checks to make sure the patient will respond to Clopidogrel after a stroke, is likely to accelerating fast. I think sales will outstrip the MT-RNR1 in the next 6 months.

All IMHO.

So just 37 times what it is, or a 3,700% gain. That seems quite good.

Looking to double in 2 months.

AI Overview

"Immatics uses the ANGLE PLC Parsortix® system as a key technology in their clinical trials to capture and harvest viable Circulating Tumor Cells (CTCs) from patient blood samples, acting as a non-invasive "liquid biopsy". This allows them to analyze the molecular and genetic makeup of the cancer without requiring invasive solid tissue biopsies.".

=======================

Two massively important questions.

1. Will the on-going Immatics cancer drug trial, which is in phase 3, pass and get FDA approval?

2. Is Cellbxhealths Parsortix machine vital to find suitable candidates and enable the programing of the "T" cells?

- If the trial gets clearance for use and Parsortix is vital, or at least the preferred method of catching the CTC's then Cellbxhealth's share price will be multiples of its present value.

We Wait.

All IMHO.

AI Overview

United Arab Emirates.

The Abu Dhabi Crude Oil Pipeline (ADCOP), also known as the Habshan–Fujairah pipeline, allows the UAE to bypass the Strait of Hormuz. It transports up to 1.8 million barrels of crude per day from Habshan in Abu Dhabi to the port of Fujairah on the Gulf of Oman, enabling direct access to the Indian Ocean.

======================

Saudi Arabia.

The Saudi Arabia East-West Pipeline, known as Petroline, is the main oil conduit bypassing the Strait of Hormuz, linking Abqaiq on the east coast to Yanbu on the Red Sea. Spanning ~1,200 km (750 miles), this pipeline can transport 5–7 million barrels per day (mbpd), providing a critical Red Sea export route amidst the 2026 Hormuz blockade

======================

Why have these Countries not vastly increased the capacities of these?

What is the problem????

Straight of Hormuz. Call me mad, but WHY NOT BUILD MORE FFS!!!!!!!!!!!!!!!!

Designation from the FDA for the treatment of both cutaneous and uveal melanoma".

==================

"As of March 2026, the current addressable patient population for Immatics' anzu-cel (IMA203) PRAME cell therapy is estimated to be approximately

9,000 patients per year in the United States and EU".

==========================

Immatics use Parsortix in the Anzu-cel(IMA203) cancer drug trial, one at phase 3.

https://investors.immatics.com/press-releases

https://trial.medpath.com/news/f665dbabc720427c/immatics-advances-prame-cell-therapy-anzu-cel-toward-2027-market-launch-with-strong-phase-3-enrollment

https://immatics.com/our-pipeline/

Designation from the FDA for the treatment of both cutaneous and uveal melanoma".

Immatics use Parsortix in the Anzu-cel(IMA203) cancer drug trial, one at phase 3.

https://investors.immatics.com/press-releases

https://trial.medpath.com/news/f665dbabc720427c/immatics-advances-prame-cell-therapy-anzu-cel-toward-2027-market-launch-with-strong-phase-3-enrollment

https://immatics.com/our-pipeline/

2026, with a 3-4 month review period post submission."

==========================

About time too. Really, Genedrive seem so unbelievably slow to do........... anything.

Surely a lot of other share holders would agree.

==========================

Current status and outlook - MT-RNR1

The genedrive® MT-RNR1-ID Kit has now been implemented into routine clinical use in nine UK hospitals with a further five UK hospitals undergoing site initiations taking the total to 14 - this equates to around 10% of the NHS England available market. 31 babies with the genetic variant have been identified to date. This roll-out is being funded by a c. £500k funding package to address NICE Real World Evidence Generation Requirements. In addition, a phased national roll-out to all health boards in NHS Scotland started in Q2 FY26 as part of an £800k investment by the Scottish Government. The test has also been implemented at Dublin's Rotunda Hospital Neonatal Intensive Care Unit where it is now in routine use. Breakthrough Device Designation was received from the FDA with dialogue with the FDA ongoing on evidence requirements with a submission estimated under the de novo route with a submission potentially being planned for the end of 2026 subject to determination of costings and study design. Finally, genedrive is starting to work with a number of distributors with traction in Western Europe and the Middle East with sales channels being prepared. The test is also being used in a large hospital in the Kingdom of Saudi Arabia which could lead to a broader opportunity in a large hospital network.

============================

Risk another Company will beat us to market with a machine like our MT-RNR1 if uou ask mm. This has already taken well over a year to date.

- Genedrive need to speed up things.

All IMHO.

That is what it is there for.

"FDA 510(k) submission for CYP2C19 anticipated around June 2026, with a 3-4 month review period post submission."

======================

So assuming FDA clearance in October for the CYP2C19 machine how is it going to be marketed in the USA?

A.I. "As of March 2026, Genedrive plc has not yet announced a final commercial marketing or distribution partner for its flagship pharmacogenetic products in the general US healthcare market".

=============

They need to "get their finger out" and get on with this NOW. Presumably there are ways to "get the word out" in the USA that they will be looking for ways to sell the machine in the USA. A small manufacturing capability for starters in the USA might be wise as well. Something that can be easily increased should the demand rise.

All IMHO.

Is incredibly frustrating. As a shareholder I feel there is a MAJOR problem with the sales side of Genedrive. The two products seem absolutely fantastic. It seems to me they would save any Countries health system a huge amount of money and indeed save lives. Yet the sales side of Genedrive are progressing at a snails pace. In my view they really need to sort this out. Then there are the FDA applications. We are still looking at June for the or the CYP2C19 (the stroke one). Incredibly the MT-RNR1 is pencilled in for November would you believe. Not good enough IMHO.

All IMHO.

The MT-RNR1 is not used in loads more neonatal wards all over the World already. One would have thought most parents on Earth would want their baby tested using the MT-RNR1 to make sure the baby does not have a bad reaction to aminoglycoside antibiotics and possibly end up DEAF!! I find it quite ridiculous these machines are not already widely used.......... in the World. It has GOT TO HAPPEN!

======================

The sales side of Genedrive need to get their act together IMHO.

All IMHO.